Is there such a thing as protocol immunosuppression in liver transplantation?

References

• Haddad EM, McAlister VC, Renouf E, et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006;18(4):CD005161
   Google Scholar
• Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7(5):442-50
   PubMed Web of Science ®Google Scholar
• Lerut J, Mathys J, Verbaandert C, et al. Tacrolimus monotherapy in liver transplantation: one year results of a prospective randomised double blind placebo controlled study. Ann Surg 2008;248(6):956-67
   PubMed Web of Science ®Google Scholar
• Trotter JF, Grafals M, Alsina AE. Early use of renal-sparing agents in liver transplantation: a closer look. Liver Transpl 2013;19(8):826-42
   PubMed Web of Science ®Google Scholar
• Rodríguez-Perálvarez M, Germani G, Darius T, et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2012;12(10):2797-814
   PubMedGoogle Scholar
• Asrani SK, Leise MD, West CP, et al. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology 2010;52(4):1360-70
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regime versus continued calcineurin inhibitors in liver transplant recipients: a randomized control trial. Am J Transplant 2012;12(3):694-705
   PubMed Web of Science ®Google Scholar
• Teperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 2013;19(7):675-89
   PubMed Web of Science ®Google Scholar
• Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014;14(3):701-10
   PubMed Web of Science ®Google Scholar
• Charlton MR, Wall WJ, Ojo AO, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009;15(11):S1-34
   PubMed Web of Science ®Google Scholar
• Ciesek S, Steinmann E, Iken M, et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010;138(5):1875-84
   PubMed Web of Science ®Google Scholar
• Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008;14(4):512-25
   PubMed Web of Science ®Google Scholar
• Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009;22(9):892-905
   PubMed Web of Science ®Google Scholar
• Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011;17(12):1394-403
   PubMed Web of Science ®Google Scholar
• Levy G, Villamil FG, Nevens F, et al. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. Am J Transplant 2014;14(3):635-46
   PubMed Web of Science ®Google Scholar
• Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011;11(8):1676-85
   PubMed Web of Science ®Google Scholar
• Manousou P, Cholongitas E, Samonakis D, et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut 2014;63(6):1005-13
   PubMed Web of Science ®Google Scholar
• McKenna GJ, Trotter JF, Klintmalm E, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. Am J Transplant 2011;11(11):2379-87
   PubMed Web of Science ®Google Scholar
• Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012;18(9):1029-36
   PubMed Web of Science ®Google Scholar
• Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18(1):62-9
   PubMed Web of Science ®Google Scholar
• Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37(4):411-19
   PubMed Web of Science ®Google Scholar
• McCaughan GW, Vajdic CM. De novo malignant disease after liver transplantation? Risk and surveillance strategies. Liver Transpl 2013;19(Suppl 2):S62-7
   Google Scholar
• Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver Transplantation: immunosuppression and oncology. Curr Opin Organ Transplant 2014;19(3):253-60
   PubMed Web of Science ®Google Scholar
• Hubscher S. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors and outcome. Liver Transpl 2001;7(4):285-91
   PubMed Web of Science ®Google Scholar
• Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004;10(4):488-91
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Lindström L, Cvancarova M, et al. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(5):517-23
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014;14(4):779-87
   PubMed Web of Science ®Google Scholar
• Londoño MC, Rimola A, O’Grady J, Sanchez-Fueyo A. Immunosuppression minimization vs. complete drug withdrawal in liver transplantation. J Hepatol 2013;59:872-9
   PubMed Web of Science ®Google Scholar
• Manzia TM, Angelico R, Baiocchi L, et al. The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up. Transpl Int 2013;26(3):259-66
   PubMed Web of Science ®Google Scholar